Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05776316 · ClinicalTrials.gov registry record · NA
Harm Reduction Services
A NA study of Substance Abuse and Drug Use, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 3
- Study locations
NCT05776316: Recruiting NA study of Substance Abuse and Drug Use, sponsored by NYU Langone Health.
NCT05776316 is a NA study of Substance Abuse and Drug Use that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 200 participants, below the 5,256-participant average among 58 other Substance Abuse trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05776316, a NA study of Substance Abuse and Drug Use, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).
Primary Outcome
Measure of engagement.
Conditions Studied
Interventions
- BEHAVIORAL Integrated Harm Reduction Intervention (IHRI)
Study Locations (3)
New York
- NYU Langone Health - New York
- Nathan Kline Institute - Orangeburg
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2028-03-28 |
| Phase | NA |
What NCT05776316 shows while recruiting
NCT05776316 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 5,256-participant average among 58 other Substance Abuse trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Substance Abuse appearing as the primary indexed condition, and to 1 intervention - of which Integrated Harm Reduction Intervention (IHRI) is the first listed.
NCT05776316 reports a single indexed study location in New York, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05776316 about?
NCT05776316 is a clinical study titled "Harm Reduction Services". The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).
What is the current status of trial NCT05776316?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-11-25. Estimated completion is 2028-03-28.
What conditions does trial NCT05776316 study?
This clinical trial studies the following conditions: Substance Abuse, Drug Use, Mental Illness.
What interventions are being tested in trial NCT05776316?
The interventions under investigation include: Integrated Harm Reduction Intervention (IHRI) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05776316?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05776316 being conducted?
This trial has 3 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05776316's enrollment target sits among peer trials
200 24th of 58 higher than 35 of 58 other Substance Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Testing ALERT With GTO in Middle Schools
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
The STop UNhealthy Substance Use Now Trial
RECRUITING · NA
-
The Trans-Led Care Study
RECRUITING · NA
-
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI